INSMED INC Finance Lease, Right-of-Use Asset, Amortization
INSMED INC (INSM) reported Finance Lease, Right-of-Use Asset, Amortization of $1.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- INSMED INC finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $678.00K, a 0.00% change year-over-year.
- INSMED INC finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $678.00K, a 0.00% change year-over-year.
- INSMED INC finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $678.00K, a 0.00% change year-over-year.
- INSMED INC finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $678.00K, a 0.00% change year-over-year.
- INSMED INC finance lease, right-of-use asset, amortization for fiscal 2025 was $2.71M, a 0.00% change from fiscal 2024.
- INSMED INC finance lease, right-of-use asset, amortization for fiscal 2024 was $2.71M, a 0.00% change from fiscal 2023.
- INSMED INC finance lease, right-of-use asset, amortization for fiscal 2023 was $2.71M, a 38.37% increase from fiscal 2022.
- INSMED INC finance lease, right-of-use asset, amortization for fiscal 2022 was $1.96M, a 81.82% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.36M 10-Q · filed 2026-08-06 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $678.00K 10-Q · filed 2026-05-07 | $1.36M derived: sum of 2 quarters · filed 2026-05-07 | $2.03M derived: sum of 3 quarters · filed 2026-05-07 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.36M derived: sum of 2 quarters · filed 2026-02-19 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | $2.71M 10-K · filed 2026-02-19 |
| 2025-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.36M derived: sum of 2 quarters · filed 2026-08-06 | $2.03M 10-Q · filed 2025-10-30 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.36M 10-Q · filed 2026-08-06 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $678.00K 10-Q · filed 2026-05-07 | $1.36M derived: sum of 2 quarters · filed 2026-05-07 | $2.03M derived: sum of 3 quarters · filed 2026-05-07 | $2.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.36M derived: sum of 2 quarters · filed 2026-02-19 | $2.03M derived: sum of 3 quarters · filed 2026-02-19 | $2.71M 10-K · filed 2026-02-19 |
| 2024-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.36M derived: sum of 2 quarters · filed 2025-10-30 | $2.03M 10-Q · filed 2025-10-30 | $2.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.36M 10-Q · filed 2025-08-07 | $2.03M derived: sum of 3 quarters · filed 2026-02-19 | $2.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $678.00K 10-Q · filed 2025-05-08 | $1.36M derived: sum of 2 quarters · filed 2026-02-19 | $2.03M derived: sum of 3 quarters · filed 2026-02-19 | $2.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.36M derived: sum of 2 quarters · filed 2026-02-19 | $2.03M derived: sum of 3 quarters · filed 2026-02-19 | $2.71M 10-K · filed 2026-02-19 |
| 2023-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.36M derived: sum of 2 quarters · filed 2024-10-31 | $2.03M 10-Q · filed 2024-10-31 | $2.15M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.36M 10-Q · filed 2024-08-08 | $1.47M derived: sum of 3 quarters · filed 2025-02-20 | $1.95M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $678.00K 10-Q · filed 2024-05-09 | $792.00K derived: sum of 2 quarters · filed 2025-02-20 | $1.27M derived: sum of 3 quarters · filed 2025-02-20 | $1.91M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $595.00K derived: sum of 2 quarters · filed 2025-02-20 | $1.23M derived: sum of 3 quarters · filed 2025-02-20 | $1.96M 10-K · filed 2025-02-20 |
| 2022-09-30 | $481.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.12M derived: sum of 2 quarters · filed 2023-10-26 | $1.85M 10-Q · filed 2023-10-26 | $2.12M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.36M 10-Q · filed 2023-08-03 | $1.63M derived: sum of 3 quarters · filed 2024-02-22 | $1.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $729.00K 10-Q · filed 2023-05-04 | $998.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.27M derived: sum of 3 quarters · filed 2024-02-22 | $1.54M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $539.00K derived: sum of 2 quarters · filed 2024-02-22 | $808.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.08M 10-K · filed 2024-02-22 |
| 2021-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $539.00K derived: sum of 2 quarters · filed 2022-10-27 | $809.00K 10-Q · filed 2022-10-27 | $1.08M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $269.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $539.00K 10-Q · filed 2022-08-04 | $808.00K derived: sum of 3 quarters · filed 2023-02-23 | $896.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $270.00K 10-Q · filed 2022-05-05 | $539.00K derived: sum of 2 quarters · filed 2023-02-23 | $627.00K derived: sum of 3 quarters · filed 2023-02-23 | $988.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $357.00K derived: sum of 2 quarters · filed 2023-02-23 | $718.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.08M 10-K · filed 2023-02-23 |
| 2020-09-30 | $88.00K 10-Q · filed 2020-10-29 | $449.00K derived: sum of 2 quarters · filed 2020-10-29 | $809.00K 10-Q · filed 2021-10-28 | $1.17M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-30 | $361.00K 10-Q · filed 2020-08-06 | $720.00K 10-Q · filed 2021-08-05 | $1.08M derived: sum of 3 quarters · filed 2022-02-17 | $1.08M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-03-31 | $360.00K 10-Q · filed 2021-05-06 | $720.00K derived: sum of 2 quarters · filed 2022-02-17 | $720.00K derived: sum of 3 quarters · filed 2022-02-17 | $720.00K derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-31 | $360.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $360.00K derived: sum of 2 quarters · filed 2022-02-17 | $360.00K derived: sum of 3 quarters · filed 2022-02-17 | $360.00K 10-K · filed 2022-02-17 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |